CAMP
NASDAQCAMP4 Therapeutics Corporation
IPO2024
Price$4.11+0.03 (+0.74%)
02:30 PM07:45 PM
News · 26 weeks42-89%
2025-12-142026-06-07
Mix2090d
- SEC Filings6(30%)
- Insider6(30%)
- Other6(30%)
- Leadership1(5%)
- Analyst1(5%)
Latest news
25 items- PRCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Compan
- SECSEC Form SCHEDULE 13G filed by CAMP4 Therapeutics CorporationSCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related DisorderCMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model Results build upon prior preclinical evidence of neurodevelopmental benefit and suggest the potential for broader therapeutic impact CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the presentation of new precl
- SECSEC Form 10-Q filed by CAMP4 Therapeutics Corporation10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Reports First Quarter 2026 Financial Results and Corporate HighlightsSubmitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 Received Orphan Designation for CMP-002 by the European Medicines Agency (EMA) Entered into collaboration with CURE SYNGAP1 to support ProMMiS, a natural history study to advance understanding of SYNGAP1 related disorder Cash runway expected into 2028, with $99 million in cash and cash equivalents as of 3/31/26 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company develop
- PRCAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene UpregulationUsing epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human cells New research enables the discovery of antisense oligonucleotides (ASOs) to increase expression of disease-relevant genes for therapeutic potential CAMBRIDGE, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to
- SECSEC Form DEFA14A filed by CAMP4 Therapeutics CorporationDEFA14A - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form DEF 14A filed by CAMP4 Therapeutics CorporationDEF 14A - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on April 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry
- ANALYSTRodman & Renshaw initiated coverage on CAMP4 Therapeutics with a new price targetRodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00
- INSIDERSEC Form 4 filed by Tardiff Daniel4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Maricich Yuri4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Gold Kelly4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Mandel-Brehm Josh4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Maclean Michael F4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 3 filed by new insider Maclean Michael F3 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Leadership Update8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Appoints Michael MacLean to its Board of DirectorsCAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr
- PRCAMP4 to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare ConferenceFormat:Fireside ChatDate and Time:March 9, 2026, 8:40 a.m. ETLocation:Miami, FLWebcast Link:Click Here Stifel CNS ForumFormat:Corporate PresentationDate and Time:March 17, 2026, 10:00 a.m.
- SECSEC Form S-8 filed by CAMP4 Therapeutics CorporationS-8 - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form 10-K filed by CAMP4 Therapeutics Corporation10-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Reports Full Year 2025 Financial Results and Corporate HighlightsGLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028 CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDA
CAMP FAQ
5 questionsWhat does CAMP4 Therapeutics Corporation do?
CalAmp Corp. provides in telematics systems, and software and subscription services in the United States, Europe, the Middle East, Africa, South America, Asia and Pacific Rim, and internationally. The company offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things market, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from...Where does CAMP stock trade?
CAMP4 Therapeutics Corporation (CAMP) is listed on NASDAQ.When did CAMP4 Therapeutics Corporation go public?
CAMP4 Therapeutics Corporation (CAMP) completed its IPO in 2024.What are analysts saying about CAMP?
CAMP4 Therapeutics Corporation has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $700.00 price target on 2026-04-14. Recent price targets range from $700.00 to $2300.00.How can I track CAMP on Quantisnow?
Quantisnow aggregates CAMP4 Therapeutics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAMP to receive live email and push alerts on every new disclosure.